Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease. METHODS: Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel-Haenszel procedure used to estimate odds ratios across centers. RESULTS: All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non-Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non-Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. CONCLUSIONS: Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A compartment located at the trans Golgi where autolysosomes and MTOR accumulate during RAS-induced senescence”
From Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). (2016) · cites this paper as [1769]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE
WOOLF, B. (1955) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1955.tb01348.x · Cited by 2,723
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696 · cited 1×
“R496H (7 recombinant alleles) (10) c.84dupG ( 17 )”
Self-citationGaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Self-citationMutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Self-citationOccurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401
Self-citationGaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399 · cited 7×
“Patients 311 (0) 186:123 (2) NP 7 (2) Controls 473 (0) 267:206 64.1 8 ( 2 )”
InfluentialSelf-citationGlucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Parkinsonism among Gaucher disease carriers
Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., McInerney-Leo, A., & Sidransky, E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024455 · Cited by 366
Self-citation
Research works printed but not linked: 1
- 10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b · doi:10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b
Cited by
Items 801–900 of 1,008
Genetic and Clinical Predictors of Deep Brain Stimulation in Young‐Onset Parkinson's Disease
Pal, G. D., Hall, D. A., Ouyang, B., Phelps, J., Alcalay, R. N., Pauciulo, M. W., Nichols, W. C., Clark, L. N., Mejia‐Santana, H., Blasucci, L. M., et al. (2016) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12309 · Cited by 35
Self-citationGlucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment
Schapira, A. H. V., Chiasserini, D., Beccari, T., & Parnetti, L. (2016) · Movement Disorders · doi:10.1002/mds.26616 · Cited by 38
Jones, E. E., Zhang, W., Zhao, X., Quiason, C. M., Dale, S., Shahidi-Latham, S. K., Grabowski, G. A., Setchell, K. D. R., Drake, R. R., & Sun, Y. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217719372 · Cited by 38
“Although type 1 GD patients experience a highly variable visceral disease and typically remain free of CNS involvement, they have a much greater lifetime risk of developing Parkinson’s disease and Lewy body disease.(5,6) Enzyme replacement therapy (ERT) has proven successful in treating the visceral manifestations of…”
BackgroundNovel Targets for Parkinson’s Disease: Addressing Different Therapeutic Paradigms and Conundrums
Rane, P., Sarmah, D., Bhute, S., Kaur, H., Goswami, A., Kalia, K., Borah, A., Dave, K. R., Sharma, N., & Bhattacharya, P. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00180 · Cited by 37
Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?
Farfel‐Becker, T., Do, J., Tayebi, N., & Sidransky, E. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.05.010 · Cited by 40
Self-citationClemente, F., Matassini, C., Faggi, C., Giachetti, S., Cresti, C., Morrone, A., Paoli, P., Goti, A., Martínez‐Bailén, M., & Cardona, F. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103740 · Cited by 35
Polinski, N. K., Martinez, T. N., Gorodinsky, A., Gareus, R., Sasner, M., Herberth, M. T., Switzer, R., Ahmad, S. O., Cosden, M. L., Kandebo, M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252325 · Cited by 40
“Mutations in the gene GBA1, which encodes the lysosomal enzyme glucocerebrosidase (GCase), have been linked to PD, and are now recognized to collectively be the greatest known genetic risk factor for development of idiopathic PD [3].”
BackgroundNext-Generation Sequencing Analysis of GBA1: The Challenge of Detecting Complex Recombinant Alleles
Woo, E. G., Tayebi, N., & Sidransky, E. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.684067 · Cited by 36
“Variants in GBA1 are a significant genetic risk factor for Define- Parkinson disease (PD) (Sidransky et al., 2009).”
BackgroundSelf-citationOftedal, L., Maple‐Grødem, J., Dalen, I., Tysnes, O., Pedersen, K. F., Alves, G. W., & Lange, J. (2022) · Neurology · doi:10.1212/wnl.0000000000201418 · Cited by 38
Glucocerebrosidase mutations in Thai patients with Parkinson's disease
Pulkes, T., Choubtum, L., Chitphuk, S., Thakkinstian, A., Pongpakdee, S., Kulkantrakorn, K., Hanchaiphiboolkul, S., Tiamkao, S., & Boonkongchuen, P. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.06.007 · Cited by 37
“However, each population appeared to have its own unique and rare mutations [8,10,11].”
BackgroundKnowledge of and Interest in Genetic Results Among Parkinson Disease Patients and Caregivers
Sakanaka, K., Waters, C., Levy, O. A., Louis, E. D., Chung, W. K., Marder, K. S., & Alcalay, R. N. (2013) · Journal of Genetic Counseling · doi:10.1007/s10897-013-9618-y · Cited by 35
Self-citationDarweesh, S. K. L., Wolters, F. J., Hofman, A., Stricker, B. H. C., Koudstaal, P. J., & Ikram, M. A. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glw122 · Cited by 38
Ophthalmic manifestations of Gaucher disease: the most common lysosomal storage disorder
Winter, A. W., Salimi, A., Ospina, L. H., & Roos, J. C. P. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-312846 · Cited by 35
PINK1 is a target of T cell responses in Parkinson’s disease
Williams, G. P., Freuchet, A., Michaelis, T., Frazier, A., Tran, N. K., Lima-Júnior, J. R., Phillips, E. J., Mallal, S. A., Litvan, I., Goldman, J. G., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180478 · Cited by 39
Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies
Johansen, K. K., White, L. R., Sando, S. B., & Aasly, J. O. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.02.015 · Cited by 42
“Patients carrying such mutations are less likely to have asymmetry at onset, tremor, and bradykinesia, and more likely to have cognitive decline, which could indicate a more DLB or PDD-like phenotype [53].”
BackgroundSelf-citationCommon pathogenic pathways in melanoma and Parkinson disease
Paisán‐Ruiz, C., & Houlden, H. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fb4466 · Cited by 34
Montine, T. J., & Montine, K. S. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150656 · Cited by 34
“The most common causative genetic mutations for PD occur in LRRK2, whereas the most common risk mutations for PD occur in GBA (Paisán-Ruíz et al., 2004; Sidransky et al., 2009; Verstraeten et al., 2015).”
BackgroundMulticenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Papapetropoulos, S. (2010) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(10)79187-0 · Cited by 34
Genetic Modifiers in Neurodegeneration
Jain, N., & Chen-Plotkin, A. S. (2018) · Current Genetic Medicine Reports · doi:10.1007/s40142-018-0133-1 · Cited by 30
Kim, M. J., Jeong, H., & Krainc, D. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac047 · Cited by 36
Placci, M., Giannotti, M. I., & Muro, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114683 · Cited by 38
Gauchers Disease—A Reappraisal of Hematopoietic Stem Cell Transplantation
Ito, S., & Barrett, A. J. (2013) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2012.762076 · Cited by 34
Induced pluripotent stem cell models of lysosomal storage disorders
Borger, D. K., McMahon, B., Lal, T. R., Serra‐Vinardell, J., Aflaki, E., & Sidransky, E. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.029009 · Cited by 36
“…population studies have established that individuals with GBA1 mutations, both carriers and affected individuals, are at an increased risk of developing Parkinson’s disease, an age-related neurodegenerative disorder, as well as other Lewy body disorders (Nalls et al., 2013; Sidransky et al., 2009).”
BackgroundSelf-citationPastores, G. M. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0850-x · Cited by 33
“In an ethnically diverse group of patients with PD screened for two GBA mutations, L444P and N370S, either mutation was found in 15% of patients and 3% of controls among Ashkenazi Jewish subjects, and in 3% of patients and less than 1% of controls among non-Jewish populations [ 23 ].”
BackgroundBrekk, O. R., Moskites, A., Isacson, O., & Hallett, P. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-33474-z · Cited by 34
Epigenetic inactivation of the autophagy–lysosomal system in appendix in Parkinson’s disease
Gordevičius, J., Li, P., Marshall, L. L., Killinger, B. A., Lang, S., Ensink, E., Kuhn, N. C., Cui, W., Maroof, N., Lauria, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25474-x · Cited by 38
Deen, M. C., Zhu, Y., Gros, C., Na, N., Gilormini, P., Shen, D. L., Bhosale, S., Anastasi, N., Wang, R., Shan, X., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200553119 · Cited by 34
Mechanisms of Glucocerebrosidase Dysfunction in Parkinson’s Disease
Chatterjee, D., & Krainc, D. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168023 · Cited by 34
Genetic insights into immune mechanisms of Alzheimer’s and Parkinson’s disease
Nott, A., & Holtman, I. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168539 · Cited by 36
Glucocerebrosidase L444P mutation confers genetic risk for Parkinson’s disease in central China
Wang, Y., Liu, L., Xiong, J., Zhang, X., Chen, Z., Yu, L., Chen, C., Huang, J., Zhang, Z., Mohmed, A. A., et al. (2012) · Behavioral and Brain Functions · doi:10.1186/1744-9081-8-57 · Cited by 35
Self-citationYang, J., Hertz, E., Zhang, X., Leinartaité, L., Lundius, E. G., Li, J., & Svenningsson, P. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.11.023 · Cited by 37
Oxidative damage and redox in Lysosomal Storage Disorders: Biochemical markers
Donida, B., Jacques, C. E. D., Mescka, C. P., Rodrigues, D. G. B., Marchetti, D. P., Ribas, G. S., Giugliani, R., & Vargas, C. R. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.01.007 · Cited by 36
Huertas, I., Jesús, S., Gómez, F. J. G., Lojo-Ramírez, J. A., Bernal‐Bernal, I., Bonilla‐Toribio, M., Martin‐Rodríguez, J. F., García-Solís, D., Gómez‐Garre, P., & Mir, P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175560 · Cited by 38
Shimohama, S., & Kawamata, J. (2018) · Springer eBooks · doi:10.1007/978-981-10-8488-1_8 · Cited by 39
Autophagy dysfunction in peripheral blood mononuclear cells of Parkinson’s disease patients
Papagiannakis, N., Xilouri, M., Koros, C., Simitsi, A., Stamelou, M., Maniati, M., & Stefanis, L. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.04.003 · Cited by 33
Sensory neuropathy and nociception in rodent models of Parkinson's disease
Valek, L., Auburger, G. W. J., & Tegeder, I. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.039396 · Cited by 37
Fajardo-Serrano, A., Rico, A. J., Roda, E., Honrubia, A., Arrieta, S., Ariznabarreta, G., Chocarro, J., Lorenzo-Ramos, E., Pejenaute, A., Vázquez, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126389 · Cited by 32
Zhou, Y., Wang, Y., Wan, J., Zhao, Y., Pan, H., Zeng, Q., Zhou, X. C., He, R., Zhou, X., Xiang, Y., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00571-4 · Cited by 32
Self-citationIncreased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease
Marano, M., Zizzo, C., Malaguti, M. C., Bacchin, R. A., Cavallieri, F., Micco, R. D., Spagnolo, F., Bentivoglio, A. R., Schirinzi, T., Bovenzi, R., et al. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107023 · Cited by 32
Kim, Y. J., Lyoo, C. H., Hong, S., Kim, N. Y., & Lee, M. S. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.01.010 · Cited by 32
LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder
Bencheikh, B. O. A., Ruskey, J. A., Arnulf, I., Dauvilliers, Y. A., Monaca, C. C., Cock, V. C. D., Gagnon, J., Spiegelman, D., Hu, M. T. M., Högl, B., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.03.019 · Cited by 32
“GBA mutations are probably the most common genetic risk factor for PD [2], are also common in DLB [3], and strongly associated with RBD [4,5].”
BackgroundSelf-citationThe Association between E326K of GBA and the Risk of Parkinson’s Disease
Huang, Y., Deng, L., Zhong, Y., & Yi, M. (2018) · Parkinson s Disease · doi:10.1155/2018/1048084 · Cited by 32
Yahalom, G., Rigbi, A., Israeli‐Korn, S., Krohn, L., Rudakou, U., Ruskey, J. A., Benshimol, L., Tsafnat, T., Gan‐Or, Z., Hassin‐Baer, S., et al. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191829 · Cited by 33
Self-citationGenetic diversity of axon degenerative mechanisms in models of Parkinson's disease
Peters, O. M., Weiss, A., Metterville, J., Song, L., Logan, R. A., Smith, G. A., Schwarzschild, M. A., Mueller, C., Brown, R. H., & Freeman, M. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105368 · Cited by 33
Brunialti, E., Villa, A. M., Mekhaeil, M., Mornata, F., Vegeto, E., Maggi, A. C., Monte, D. A. D., & Ciana, P. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02272-2 · Cited by 32
Viel, C., Clarke, J. L., Kayatekin, C., Richards, A. M., Chiang, M. S. R., Park, H. J., Wang, B., Shihabuddin, L. S., & Sardi, S. P. (2021) · Scientific Reports · doi:10.1038/s41598-021-00404-5 · Cited by 33
Ren, J., Zhang, R., Pan, C., Xu, J., Sun, H., Hua, P., Zhang, L., Zhang, W., Xu, P., Ma, C., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15230 · Cited by 33
Role of Lysosomal Gene Variants in Modulating GBA ‐Associated Parkinson's Disease Risk
Straniero, L., Rimoldi, V., Monfrini, E., Bonvegna, S., Melistaccio, G., Lake, J., Soldà, G., Aureli, M., Shankaracharya, Keagle, P. J., et al. (2022) · Movement Disorders · doi:10.1002/mds.28987 · Cited by 36
Mavroeidi, P., Vetsi, M., Dionysopoulou, D., & Xilouri, M. (2022) · Biomolecules · doi:10.3390/biom12070957 · Cited by 33
Siwecka, N., Saramowicz, K., Galita, G., Rozpędek‐Kamińska, W., & Majsterek, I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082051 · Cited by 33
“GBA gene mutations are the main causative agent of a rare lysosomal storage disorder, Gaucher disease, and the most common genetic risk factor for PD (7–10% of PD patients) [69].”
BackgroundHu, F., Xi, J., Guo, J., Yu, L., Liu, L., He, X., Liu, Z.-L., Zou, X. ‐., & Xu, Y. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03097.x · Cited by 36
Rare variants in LRRK1 and Parkinson's disease
Schulte, E. C., Ellwanger, D. C., Dihanich, S., Manzoni, C., Stangl, K., Schormair, B., Graf, E., Eck, S. H., Mollenhauer, B., Haubenberger, D., et al. (2013) · Neurogenetics · doi:10.1007/s10048-013-0383-8 · Cited by 37
Aetiopathogenesis of Parkinson’s disease
Schapira, A. H. V. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6016-y · Cited by 34
Glucocerebrosidase enzyme activity in GBA mutation Parkinson’s disease
Ortega, R. A., Torres, P., Swan, M. C., Nichols, W. C., Boschung, S., Raymond, D., Barrett, M. J., Johannes, B. A., Severt, L., Shanker, V., et al. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.12.004 · Cited by 34
“Heterozygous glucocerebrosidase enzyme (GCase) mutations (from the glucocerebrosidase gene [GBA1]) encode lysosomal GCase and increase the risk of Parkinson’s disease (PD) and dementia with Lewy bodies [1,2].”
BackgroundLunde, K. A., Chung, J., Dalen, I., Pedersen, K. F., Linder, J., Domellöf, M., Elgh, E., Macleod, A. D., Tzoulis, C., Larsen, J. P., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.04.006 · Cited by 35
Nanopore sequencing of the glucocerebrosidase (GBA) gene in a New Zealand Parkinson's disease cohort
Graham, O. E. E., Pitcher, T. L., Liau, Y., Miller, A. L., Dalrymple‐Alford, J. C., Anderson, T., & Kennedy, M. A. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.11.022 · Cited by 32
Lysosomal Storage Disorders Shed Light on Lysosomal Dysfunction in Parkinson’s Disease
Blumenreich, S., Barav, O. B., Jenkins, B., & Futerman, A. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144966 · Cited by 36
“Mutations in one of these lysosomal genes, namely GBA1, result in Gaucher disease (GD) [6], and mutations in GBA1 are now recognized as the highest genetic risk factor for Parkinson’s disease (PD) [7].”
BackgroundResultInfluentialEndosomal-Lysosomal Processing of Neurodegeneration-Associated Proteins in Astrocytes
Wong, C.-O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145149 · Cited by 31
Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease
Vieira, S. R. L., Mezabrovschi, R., Toffoli, M., Pozo, S. L. D., Menozzi, E., Mullin, S., Yalkic, S., Limbachiya, N., Koletsi, S., Loefflad, N., et al. (2024) · Movement Disorders · doi:10.1002/mds.30006 · Cited by 33
Self-citationWilliams, D., Glasstetter, L. M., Jong, T. T., Chen, T., Kapoor, A., Zhu, S., Zhu, Y., Calvo, R., Gehrlein, A., Wong, K., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406009121 · Cited by 34
Self-citationLewy pathology formation in patient-derived GBA1 Parkinson’s disease midbrain organoids
Frattini, E., Faustini, G., Lopez, G., Carsana, E. V., Tosi, M., Trezzi, I., Magni, M., Soldà, G., Straniero, L., Facchi, D., et al. (2024) · Brain · doi:10.1093/brain/awae365 · Cited by 37
Zhao, F., Bi, L., Wang, W., Wu, X., Li, Y., Gong, F., Lu, S., Feng, F., Qian, Z., Hu, C., et al. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.02.007 · Cited by 33
Self-citationThe hidden Niemann-Pick type C patient: clinical niches for a rare inherited metabolic disease
Hendriksz, C. J., Anheim, M., Bauer, P., Bonnot, O., Chakrapani, A., Corvol, J., de Koning, T. J., Degtyareva, А. V., Dionisi‐Vici, C., Doss, S., et al. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1294054 · Cited by 37
Precision Medicine: Functional Advancements
Caskey, C. T. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-041316-090905 · Cited by 35
Jiang, Z., Huang, Y., Zhang, P., Han, C., Lu, Y., Mo, Z., Zhang, Z., Li, X., Zhao, S., Cai, F., et al. (2020) · Molecular Brain · doi:10.1186/s13041-020-00637-x · Cited by 32
“Genetic and clinical studies confirmed that GBA mutations were more prevalent in PD patients than in other populations [6, 7].”
BackgroundSelf-citationJewett, K. A., Thomas, R. E., Phan, C. Q., Lin, B. C., Milstein, G., Yu, S., Bettcher, L., Neto, F. C., Djukovic, D., Raftery, D., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1008859 · Cited by 32
Mingione, A., Pivari, F., Plotegher, N., Dei, M., Zulueta, A., Bocci, T., Trinchera, M., Albi, E., Maglione, V., Caretti, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126469 · Cited by 32
Drug repurposing strategies of relevance for Parkinson’s disease
Fletcher, E. J. R., Kaminski, T. W., Williams, G. H., & Duty, S. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.841 · Cited by 32
Planning for Prevention of Parkinson Disease: Now Is the Time
Crotty, G. F., Keavney, J. L., Alcalay, R. N., MAREK, K. L., Marshall, G. A., Rosas, H. D., & Schwarzschild, M. A. (2022) · Neurology · doi:10.1212/wnl.0000000000200789 · Cited by 35
Plasma sphingolipid abnormalities in neurodegenerative diseases
Oizumi, H., Sugimura, Y., Totsune, T., Kawasaki, I., Ohshiro, S., Baba, T., Kimpara, T., Sakuma, H., Hasegawa, T., Kawahata, K., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279315 · Cited by 36
“Heterozygous GBA1 mutation carriers exhibit much greater incidence of PD than the general population [32, 33].”
BackgroundNo association of GBA mutations and multiple system atrophy
Srulijes, K., Hauser, A. ‐., Guella, I., Asselta, R., Brockmann, K., Schulte, C., Soldà, G., Cilia, R., Maetzler, W., Schöls, L. J., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12086 · Cited by 32
Self-citationGenetic Movement Disorders in Patients of Jewish Ancestry
Inzelberg, R., Hassin‐Baer, S., & Jankovic, J. J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1364 · Cited by 31
Crosiers, D., Verstraeten, A., Wauters, E., Engelborghs, S., Peeters, K., Mattheijssens, M., Deyn, P. P. D., Theuns, J., Broeckhoven, C. V., & Cras, P. P. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.07.008 · Cited by 32
Schlossmacher, M. G., Tomlinson, J. J., dos Santos, G. M., Shutinoski, B., Brown, E. G., Manuel, D. G., & Mestre, T. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13476 · Cited by 32
Isacson, O., Brekk, O. R., & Hallett, P. J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01053 · Cited by 32
“Haploinsufficiency of GBA1, which causes reduced activity of glucocerebrosidase (GCase), is associated clinically with a significantly increased risk of PD and LBD, and with faster rate of cognitive decline in α-synucleinopathies, including LBD and PD (3, 4).”
BackgroundThe annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1
Gustavsson, E. K., Sethi, S., Gao, Y., Brenton, J. W., García-Ruiz, S., Zhang, D., Garza, R., Reynolds, R. H., Evans, J. R., Chen, Z., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk1296 · Cited by 30
New Directions in Gaucher Disease
Horowitz, M., Elstein, D., Zimran, A., & Göker-Alpan, Ö. (2016) · Human Mutation · doi:10.1002/humu.23056 · Cited by 36
Hsieh, P., Wang, C., Tsai, C., Yeh, Y., Lee, Y. S., & Wu, Y. (2019) · Brain and Behavior · doi:10.1002/brb3.1281 · Cited by 34
“GBA L444P is a known risk factor for PD; in a study, it was shown to increase PD risk by 10 times (Sidransky et al., 2009).”
BackgroundSelf-citationGlucocerebrosidase as a therapeutic target for Parkinson’s disease
Chen, Y., Sam, R., Sharma, P., Chen, L., Do, J., & Sidransky, E. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1733970 · Cited by 32
Self-citationYañez, M. J., Marín, T., Balboa, E., Klein, A. D., Alvarez, A. R., & Zanlungo, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165875 · Cited by 33
Current and emerging pharmacotherapy for Gaucher disease in pediatric populations
Sam, R., Ryan, E., Daykin, E. C., & Sidransky, E. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1902989 · Cited by 34
Self-citationDrug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
Stott, S., Wyse, R. K. H., & Brundin, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653377 · Cited by 32
Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
Furderer, M. L., Hertz, E., Lopez, G. J., & Sidransky, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105842 · Cited by 30
Self-citationChoong, C., Aguirre, C., Kakuda, K., Beck, G., Nakanishi, H., Kimura, Y., Shimma, S., Nabekura, K., Hideshima, M., Doi, J., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02555-3 · Cited by 32
Russo, T., Kolisnyk, B., Aswathy, B. S., Kim, T. W., Martin, J., Plessis‐Belair, J., Ni, J., Pearson, J. A., Park, E. J., Sher, R. B., et al. (2024) · Aging Cell · doi:10.1111/acel.14077 · Cited by 32
Analysis of the genetic variability in Parkinson's disease from Southern Spain
Bandrés‐Ciga, S., Mencacci, N. E., Durán, R., Barrero, F. J., Sevilla, F. E., Morgan, S. L., Hehir, J., Vives, F., Hardy, J., & Pittman, A. M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.020 · Cited by 33
Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease
Noelker, C., Lü, L., Höllerhage, M., Vulinović, F., Sturn, A., Roscher, R., Höglinger, G. U., Hirsch, É. C., Oertel, W. H., Alvarez‐Fischer, D., et al. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.06.030 · Cited by 31
Mitochondrial dysfunction in Parkinson’s disease
Бунеева, О. А., & Medvedev, A. E. (2011) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750811040032 · Cited by 30
Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C
Gruschus, J. M., Jiang, Z., Yap, T. L., Hill, S. A., Grishaev, A., Piszczek, G., Sidransky, E., & Lee, J. C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.024 · Cited by 32
Self-citationНужный, Е. П., Emelyanov, A., Boukina, T., Tatiana, U., Yakimovskii, А. F., Zakharova, E. Y., & Пчелина, С. Н. (2015) · Movement Disorders · doi:10.1002/mds.26200 · Cited by 33
Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders
Robertson, E. E., Hall, D. A., McAsey, A., & O’Keefe, J. A. (2016) · The Clinical Neuropsychologist · doi:10.1080/13854046.2016.1202239 · Cited by 32
Zigdon, H., Meshcheriakova, A., Farfel‐Becker, T., Volpert, G., Sabanay, H., & Futerman, A. H. (2017) · FEBS Letters · doi:10.1002/1873-3468.12591 · Cited by 30
Ethnicity-Based Carrier Screening
King, J. R., & Klugman, S. D. (2018) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2017.10.010 · Cited by 30
Convergent molecular defects underpin diverse neurodegenerative diseases
Tofaris, G. K., & Buckley, N. J. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316988 · Cited by 31
Biomedical Implications of Autophagy in Macromolecule Storage Disorders
Palhegyi, A. M., Seranova, E., Dimova, S., Hoque, S., & Sarkar, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00179 · Cited by 34
“Interestingly, mutations in GBA1 gene could induce neurodegeneration and correlated with increased risk of developing Parkinson’s disease (PD) (Sidransky et al., 2009; Farfel-Becker et al., 2014).”
BackgroundGuix, F. X. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24526 · Cited by 32
“For example, Amyloid‐beta peptide (Aβ) is the main com‐ ponent of amyloid plaques found in the parenchyma of the brain of Alzheimer's disease (AD) patients (Selkoe, 1991); alpha‐synuclein is the primary component of Lewy Bodies, which are intraneu‐ ronal aggregates present in patients with Parkinson's disease (PD) or…”
BackgroundFu, Y., Zhang, J., Qin, R., Ren, Y., Zhou, T., Han, B., & Liu, B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100053 · Cited by 35
Schönemann, W., Gallienne, E., Ikeda‐Obatake, K., Asano, N., Nakagawa, S., Kato, A., Adachi, I., Górecki, M., Frelek, J., & Martin, O. R. (2013) · ChemMedChem · doi:10.1002/cmdc.201300327 · Cited by 32
Blumenreich, S., Yaacobi, C., Vardi, A., Barav, O. B., Vitner, E. B., Park, H. J., Wang, B., Cheng, S. H., Sardi, S. P., & Futerman, A. H. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15136 · Cited by 29
“…A-beta, the major component of beta-amyloid deposits, and has been suggested as a marker in Alzheimer's disease (Mocchegiani & Malavolta, 2007) although there is no evidence for A2m playing a role in Parkinson's disease, which is genetically associated with Gaucher disease (Sidransky et al., 2009).”
Backgroundα‐Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease
Isonaka, R., Goldstein, D. S., Zhu, W. Y., Yoon, E., Ehrlich, D. J., Schindler, A. B., Kokkinis, A. D., Sabir, M. S., Scholz, S. W., Bandrés‐Ciga, S., et al. (2021) · Movement Disorders · doi:10.1002/mds.28667 · Cited by 32
“Between these extremes, heterozygous mutations in GBA are considered high-risk alleles and increase PD risk by 2- to 10-fold.(7) Biallelic GBA mutations cause Gaucher disease and also increase PD risk.”
BackgroundSelf-citation
Metadata
- Authors
- Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.-M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H.-C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A. E., Lee-Chen, G.-J., Lesage, S., Marder, K., Mata, I. F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L. V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.-K., Tayebi, N., Toda, T., Troiano, A. R., Tsuji, S., Wittstock, M., Wolfsberg, T. G., Wu, Y.-R., Zabetian, C. P., Zhao, Y., & Ziegler, S. G.
- Affiliations
- National Institutes of Health (US)
- National Human Genome Research Institute (US)
- Corresponding author
- Sidransky, E.
- ORCID
- Sidransky, E.
- Nalls, M.A.
- Aasly, J.O.
- Annesi, G.
- Barbosa, E.R.
- Berg, D.
- Brice, A.
- Chen, C.-M.
- Clark, L.N.
- Condroyer, C.
- Dürr, A.
- Farrer, M.J.
- Fung, H.-C.
- Gasser, T.
- Giladi, N.
- Gurevich, T.
- Kropp, P.
- Lang, A.E.
- Lesage, S.
- Marder, K.
- Mata, I.F.
- Mirelman, A.
- Mitsui, J.
- Mizuta, I.
- Nicoletti, G.
- Oliveira, C.
- Ottman, R.
- Pereira, L.V.
- Quattrone, A.
- Rogaeva, E.
- Rosenbaum, H.
- Rozenberg, R.
- Schulte, C.
- Sharma, M.
- Singleton, A.
- Spitz, M.
- Tan, E.-K.
- Tayebi, N.
- Toda, T.
- Tsuji, S.
- Wittstock, M.
- Wolfsberg, T.G.
- Wu, Y.-R.
- Zabetian, C.P.
- Zhao, Y.
- Ziegler, S.G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-22
- Volume
- 361
- Issue
- 17
- Pages
- 1651-1661
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2856322
- OpenAlex
- W2170281382
- Cited by
- 2,135
- References
- 43
- Citations by year
- 2026: 128 · 2025: 147 · 2024: 156 · 2023: 156 · 2022: 149 · 2021: 155 · 2020: 174 · 2019: 136 · 2018: 135 · 2017: 115 · 2016: 118 · 2015: 118 · 2014: 95 · 2013: 103 · 2012: 84
- FWCI
- 54.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- National University of Singapore (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- University of Washington
- National Institutes of Health (Z99 HG999999)
- National Institute on Aging (Z01AG000957)
- National Human Genome Research Institute (ZIAHG200336)
- National Institute of Neurological Disorders and Stroke (R56NS036630, R21NS050487, NS 40256, NS050487, R01NS036630, R01NS060113, NS060113)
- National Center for Research Resources (UL1RR024156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, GBA mutations, Ashkenazi Jews, Gaucher disease, mutation frequency, genotype-phenotype correlation, atypical presentation, familial Parkinson's disease
- MeSH terms
- Aged, Genotype, Glucosylceramidase, Humans, Jews, Middle Aged, Mutation, Parkinson Disease, Multivariate Analysis, Logistic Models, Odds Ratio, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.